Association between familial Mediterranean fever and multiple sclerosis: A case series from the JIR cohort and systematic literature review.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
May 2021
Historique:
received: 27 12 2020
revised: 19 01 2021
accepted: 05 02 2021
pubmed: 21 2 2021
medline: 15 5 2021
entrez: 20 2 2021
Statut: ppublish

Résumé

Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disorder; and leads to the uncontrolled production of interleukin (IL)-1β. Multiple sclerosis (MS) is an inflammatory disease of the central nervous system; and its development seems to be partly correlated with IL-1β levels. It is hypothesized that FMF could be associated with MS. We aim to describe the features of patients displaying both diseases and to investigate the MEFV mutation rate in MS patients. Patients with definite MS were retrieved from the cohort of FMF patients in the Reference Center for Rare Auto-inflammatory Diseases and Amyloidosis (CEREMAIA). We also performed a systematic literature review of articles from PubMed that were published from 1990 to 2020. Twenty-four patients were included in the case series: five patients (1.3%) from our cohort of 364 and 19 patients from the literature. The sex ratio was 2:1. The mean age at diagnosis of FMF was 19 years old; and that for MS was 29 years old. Seven studies investigating the MEFV mutation rate in MS patients were included. Three studies found a higher mutation rate in MS patients than in the control group. FMF and MS features were comparable to those of patients with unrelated diseases; and MEFV mutation carriage was not positively correlated with MS. However; MS prevalence in FMF patients was higher than was expected in a healthy population. To a lesser extent; FMF prevalence in MS patients was higher than expected in a healthy population and the difference might not be significant. These data suggest that FMF could be associated with MS; and further studies are needed to investigate a potential causal association.

Identifiants

pubmed: 33609923
pii: S2211-0348(21)00100-0
doi: 10.1016/j.msard.2021.102834
pii:
doi:

Substances chimiques

MEFV protein, human 0
Pyrin 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102834

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Inès Elhani (I)

Sorbonne University; Internal Medicine Department; AP-HP; Hôpital Tenon; Paris; France; Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA)-JIR Cohort; France; Department of Internal Medicine; Caen; Normandie Univ; UNICAEN; CHU de Caen Normandie; France.

Anael Dumont (A)

Sorbonne University; Internal Medicine Department; AP-HP; Hôpital Tenon; Paris; France; Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA)-JIR Cohort; France; Department of Internal Medicine; Caen; Normandie Univ; UNICAEN; CHU de Caen Normandie; France.

Hélène Vergneault (H)

Sorbonne University; Internal Medicine Department; AP-HP; Hôpital Tenon; Paris; France; Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA)-JIR Cohort; France.

Samuel Ardois (S)

Sorbonne University; Internal Medicine Department; AP-HP; Hôpital Tenon; Paris; France; Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA)-JIR Cohort; France; Department of Internal Medicine; Rennes University Hospital; Rennes; France.

Maëlle Le Besnerais (M)

Department of Internal Medicine; CHU Charles Nicolle; Rouen; France.

Hervé Levesque (H)

Department of Internal Medicine; CHU Charles Nicolle; Rouen; France.

Jean-Christophe Ouallet (JC)

Department of Neurology; CHU de Bordeaux Pellegrin Tripode; Bordeaux; France.

Léa Savey (L)

Sorbonne University; Internal Medicine Department; AP-HP; Hôpital Tenon; Paris; France; Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA)-JIR Cohort; France.

Achille Aouba (A)

Department of Internal Medicine; Caen; Normandie Univ; UNICAEN; CHU de Caen Normandie; France.

Serge Amselem (S)

Department of Genetics; Sorbonne University; Hôpital Trousseau APHP; Paris; France.

Irina Giurgea (I)

Department of Genetics; Sorbonne University; Hôpital Trousseau APHP; Paris; France.

Jean Capron (J)

Department of Neurology; Hôpital Saint-Antoine APHP; Paris; France.

Gilles Grateau (G)

Sorbonne University; Internal Medicine Department; AP-HP; Hôpital Tenon; Paris; France; Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA)-JIR Cohort; France.

Sophie Georgin-Lavialle (S)

Sorbonne University; Internal Medicine Department; AP-HP; Hôpital Tenon; Paris; France; Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses Inflammatoire (CEREMAIA)-JIR Cohort; France. Electronic address: sophie.georgin-lavialle@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH